BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Chao CY, Battat R, Al Khoury A, Restellini S, Sebastiani G, Bessissow T. Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article. World J Gastroenterol 2016; 22(34): 7727-7734 [PMID: 27678354 DOI: 10.3748/wjg.v22.i34.7727]
URL: https://www.wjgnet.com/1007-9327/full/v22/i34/7727.htm
Number Citing Articles
1
Ziwei Li, Jun Zhang, Yufeng Zhang, Limin Zhou, Jiajia Zhao, Yuanfeng Lyu, Long Hin Poon, Zhixiu Lin, Kenneth Kin Wah To, Xiaoyu Yan, Zhong Zuo. Intestinal absorption and hepatic elimination of drugs in high‐fat high‐cholesterol diet‐induced non‐alcoholic steatohepatitis rats: exemplified by simvastatinBritish Journal of Pharmacology 2021; 178(3): 582 doi: 10.1111/bph.15298
2
Tingyu Dong, Jiajin Li, Yuqing Liu, Shikai Zhou, Xiang Wei, Hongting Hua, Kechao Tang, Xiaomin Zhang, Yiming Wang, Zhen Wu, Chaobing Gao, Huabing Zhang. Roles of immune dysregulation in MASLDBiomedicine & Pharmacotherapy 2024; 170: 116069 doi: 10.1016/j.biopha.2023.116069
3
Qianqian Yao, Yanan Gao, Linlin Fan, Jiaqi Wang, Nan Zheng. 2′-Fucosyllactose Remits Colitis-Induced Liver Oxygen Stress through the Gut–Liver–Metabolites AxisNutrients 2022; 14(19): 4186 doi: 10.3390/nu14194186
4
Yanlin Zhu, Shuangshuang Xu, Yi Lu, Yijuan Wei, Benqiang Yao, Fusheng Guo, Xing Zheng, Yumeng Wang, Ying He, Lihua Jin, Yong Li. Repositioning an Immunomodulatory Drug Vidofludimus as a Farnesoid X Receptor Modulator With Therapeutic Effects on NAFLDFrontiers in Pharmacology 2020; 11 doi: 10.3389/fphar.2020.00590
5
Wenxin Wang, Xin Gao, Ning Kang, Chen Wang, Chenyang Li, Huan Yu, Xiaolan Zhang. Shared biomarkers and immune cell infiltration signatures in ulcerative colitis and nonalcoholic steatohepatitisScientific Reports 2023; 13(1) doi: 10.1038/s41598-023-44853-6
6
Extraintestinal manifestations of inflammatory bowel disease, nitroxidative stress and dysbiosis: What is the link between them?BIOCELL 2021; 45(3): 461 doi: 10.32604/biocell.2021.014332
7
Elisa Carolina Lange, Pabulo Henrique Rampelotto, Larisse Longo, Laura Bainy Rodrigues de Freitas, Carolina Uribe-Cruz, Mario Reis Alvares-da-Silva. Ornithine aspartate effects on bacterial composition and metabolic pathways in a rat model of steatotic liver diseaseWorld Journal of Hepatology 2024; 16(5): 832-842 doi: 10.4254/wjh.v16.i5.832
8
Sophie Restellini, Olivier Chazouillères, Jean‐Louis Frossard. Hepatic manifestations of inflammatory bowel diseasesLiver International 2017; 37(4): 475 doi: 10.1111/liv.13265
9
Justyna Kikut, Nina Konecka, Maciej Ziętek, Małgorzata Szczuko. Inflammatory Bowel Disease Etiology: Current KnowledgePteridines 2018; 29(1): 206 doi: 10.1515/pteridines-2018-0020
10
Shu Liang, Yupei Zhang, Yuanjun Deng, Yifang He, Yinji Liang, Zien Liang, Yanning Chen, Kairui Tang, Runsen Chen, Qinhe Yang. The Potential Effect of Chinese Herbal Formula Hongqijiangzhi Fang in Improving NAFLD: Focusing on NLRP3 Inflammasome and Gut MicrobiotaEvidence-Based Complementary and Alternative Medicine 2018; 2018: 1 doi: 10.1155/2018/5378961
11
Konstantinos Arvanitakis, Theocharis Koufakis, Djordje Popovic, Giuseppe Maltese, Omar Mustafa, Michael Doumas, Olga Giouleme, Kalliopi Kotsa, Georgios Germanidis. GLP-1 Receptor Agonists in Obese Patients with Inflammatory Bowel Disease: from Molecular Mechanisms to Clinical Considerations and Practical Recommendations for Safe and Effective UseCurrent Obesity Reports 2023; 12(2): 61 doi: 10.1007/s13679-023-00506-3
12
Shaya Noorian, Yejoo Jeon, Minh T Nguyen, Jenny Sauk, Berkeley N Limketkai. The Impact of NAFLD on Hospitalization Outcomes in Patients With Inflammatory Bowel Diseases: Nationwide AnalysisInflammatory Bowel Diseases 2022; 28(6): 878 doi: 10.1093/ibd/izab199
13
Apostolis Papaefthymiou, Spyros Potamianos, Antonis Goulas, Michael Doulberis, Jannis Kountouras, Stergios A Polyzos. Inflammatory Bowel Disease-associated Fatty Liver Disease: the Potential Effect of Biologic AgentsJournal of Crohn's and Colitis 2022; 16(5): 852 doi: 10.1093/ecco-jcc/jjab212
14
Katerina Karaivazoglou, Christos Konstantakis, Evanthia Tourkochristou, Stelios F. Assimakopoulos, Christos Triantos. Non-alcoholic fatty liver disease in inflammatory bowel disease patientsEuropean Journal of Gastroenterology & Hepatology 2020; 32(8): 903 doi: 10.1097/MEG.0000000000001679
15
Hsu-Heng Yen, Pei-Yuan Su, Siou-Ping Huang, Lisha Wu, Tsui-Chun Hsu, Ya-Huei Zeng, Yang-Yuan Chen, Wan-Long Chuang. Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: A Taiwanese retrospective cohort studyPLOS ONE 2021; 16(5): e0252286 doi: 10.1371/journal.pone.0252286
16
Takahiro Nagata, Sadahiro Funakoshi, Daisuke Morihara, Satoshi Shakado, Keiji Yokoyama, Kazuhide Takata, Takashi Tanaka, Atsushi Fukunaga, Ryo Yamauchi, Hiromi Fukuda, Hiroki Matsuoka, So Imakiire, Hideto Sakisaka, Satoshi Matsuoka, Nobuaki Kuno, Koichi Abe, Hideki Ishibashi, Shinya Ashizuka, Fumihito Hirai. Malnutrition and inflammation status in nonobese patients with inflammatory bowel disease are associated with nonalcoholic fatty liver disease: a retrospective studyIntestinal Research 2023; 21(4): 471 doi: 10.5217/ir.2023.00035
17
Cholsoon Jang, Shogo Wada, Steven Yang, Bridget Gosis, Xianfeng Zeng, Zhaoyue Zhang, Yihui Shen, Gina Lee, Zoltan Arany, Joshua D. Rabinowitz. The small intestine shields the liver from fructose-induced steatosisNature Metabolism 2020; 2(7): 586 doi: 10.1038/s42255-020-0222-9
18
Yunfei Luo, Hui Lin. Inflammation initiates a vicious cycle between obesity and nonalcoholic fatty liver diseaseImmunity, Inflammation and Disease 2021; 9(1): 59 doi: 10.1002/iid3.391
19
Chungho Lee, SangAh Kim, Bobae Kim, Wilhelm H. Holzapfel, Chang-Kee Hyun, Nobuyuki Takahashi. Disturbance of lipid metabolism in germ-free mice transplanted with gut microbiota of DSS-induced colitis micePLOS ONE 2023; 18(2): e0280850 doi: 10.1371/journal.pone.0280850
20
Kamolyut Lapumnuaypol, Napatt Kanjanahattakij, David Pisarcik, Charat Thongprayoon, Karn Wijarnpreecha, Wisit Cheungpasitporn. Effects of inflammatory bowel disease treatment on the risk of nonalcoholic fatty liver disease: a meta-analysisEuropean Journal of Gastroenterology & Hepatology 2018; 30(8): 854 doi: 10.1097/MEG.0000000000001144
21
Sutapa Sarkar, Diana Kimono, Muayad Albadrani, Ratanesh K. Seth, Philip Busbee, Hasan Alghetaa, Dwayne E. Porter, Geoff I. Scott, Bryan Brooks, Mitzi Nagarkatti, Prakash Nagarkatti, Saurabh Chatterjee. Environmental microcystin targets the microbiome and increases the risk of intestinal inflammatory pathology via NOX2 in underlying murine model of Nonalcoholic Fatty Liver DiseaseScientific Reports 2019; 9(1) doi: 10.1038/s41598-019-45009-1
22
Mark A. Febbraio, Michael Karin. “Sweet death”: Fructose as a metabolic toxin that targets the gut-liver axisCell Metabolism 2021; 33(12): 2316 doi: 10.1016/j.cmet.2021.09.004
23
Sven H. Loosen, Münevver Demir, Karel Kostev, Tom Luedde, Christoph Roderburg. Incidences of hypothyroidism and autoimmune thyroiditis are increased in patients with nonalcoholic fatty liver diseaseEuropean Journal of Gastroenterology & Hepatology 2021; 33(1S): e1008 doi: 10.1097/MEG.0000000000002136
24
Scott McHenry, Matthew Glover, Ali Ahmed, Quazim Alayo, Maria Zulfiqar, Daniel R Ludwig, Matthew A Ciorba, Nicholas O Davidson, Parakkal Deepak. NAFLD Is Associated With Quiescent Rather Than Active Crohn’s DiseaseInflammatory Bowel Diseases 2024; 30(5): 757 doi: 10.1093/ibd/izad129
25
Mercedes Perez-Carreras, Begoña Casis-Herce, Raquel Rivera, Inmaculada Fernandez, Pilar Martinez-Montiel, Victoria Villena. Non-alcoholic fatty liver disease in patients with intestinal, pulmonary or skin diseases: Inflammatory cross-talk that needs a multidisciplinary approachWorld Journal of Gastroenterology 2021; 27(41): 7113-7124 doi: 10.3748/wjg.v27.i41.7113
26
Ludovico Abenavoli, Rocco Spagnuolo, Giuseppe Guido Maria Scarlata, Emidio Scarpellini, Luigi Boccuto, Francesco Luzza. Ultrasound Prevalence and Clinical Features of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Diseases: A Real-Life Cross-Sectional StudyMedicina 2023; 59(11): 1935 doi: 10.3390/medicina59111935
27
Sutapa Sarkar, Punnag Saha, Ratanesh K. Seth, Ayan Mondal, Dipro Bose, Diana Kimono, Muayad Albadrani, Avik Mukherjee, Dwayne E. Porter, Geoff I. Scott, Shuo Xiao, Bryan Brooks, John Ferry, Mitzi Nagarkatti, Prakash Nagarkatti, Saurabh Chatterjee. Higher intestinal and circulatory lactate associated NOX2 activation leads to an ectopic fibrotic pathology following microcystin co-exposure in murine fatty liver diseaseComparative Biochemistry and Physiology Part C: Toxicology & Pharmacology 2020; 238: 108854 doi: 10.1016/j.cbpc.2020.108854
28
Alvin T George, Matthew Glover, Quazim Alayo, Maria Zulfiqar, Daniel R Ludwig, Matthew A Ciorba, Scott McHenry, Parakkal Deepak. Nonalcoholic Fatty Liver Disease Is a Risk Factor for Thiopurine Hepatotoxicity in Crohn’s DiseaseCrohn's & Colitis 360 2023; 5(1) doi: 10.1093/crocol/otad005
29
Cátia Arieira, Sara Monteiro, Sofia Xavier, Francisca Dias de Castro, Joana Magalhães, Maria J. Moreira, Carla Marinho, José Cotter. Hepatic steatosis and patients with inflammatory bowel disease: when transient elastography makes the differenceEuropean Journal of Gastroenterology & Hepatology 2019; 31(8): 998 doi: 10.1097/MEG.0000000000001319
30
Rashida Ginwala, Raina Bhavsar, DeGaulle I. Chigbu, Pooja Jain, Zafar K. Khan. Potential Role of Flavonoids in Treating Chronic Inflammatory Diseases with a Special Focus on the Anti-Inflammatory Activity of ApigeninAntioxidants 2019; 8(2): 35 doi: 10.3390/antiox8020035
31
Ming Xie, Haokai Tang, Feifei Li, Si Wu, Yanhui Dong, Yide Yang, Julien Steven Baker, Jun Ma. Mediating Roles of hsCRP, TNF-α and Adiponectin on the Associations between Body Fat and Fatty Liver Disease among Overweight and Obese AdultsBiology 2021; 10(9): 895 doi: 10.3390/biology10090895
32
Zhipeng Tao, My N. Helms, Benjamin C. B. Leach, Xu Wu. Molecular insights into the multifaceted functions and therapeutic targeting of high mobility group box 1 in metabolic diseasesJournal of Cellular and Molecular Medicine 2022; 26(14): 3809 doi: 10.1111/jcmm.17448
33
Mohammad Zamani, Shaghayegh Alizadeh‐Tabari, Siddharth Singh, Rohit Loomba. Meta‐analysis: prevalence of, and risk factors for, non‐alcoholic fatty liver disease in patients with inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics 2022; 55(8): 894 doi: 10.1111/apt.16879
34
Chiara Saroli Palumbo, Sophie Restellini, Che-Yung Chao, Achuthan Aruljothy, Carolyne Lemieux, Gary Wild, Waqqas Afif, Peter L Lakatos, Alain Bitton, Sila Cocciolillo, Peter Ghali, Talat Bessissow, Giada Sebastiani. Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient ElastographyInflammatory Bowel Diseases 2019; 25(1): 124 doi: 10.1093/ibd/izy200
35
Sophie Restellini, Omar Kherad, Talat Bessissow, Charles Ménard, Myriam Martel, Maryam Taheri Tanjani, Peter L Lakatos, Alan N Barkun. Systematic review and meta-analysis of colon cleansing preparations in patients with inflammatory bowel diseaseWorld Journal of Gastroenterology 2017; 23(32): 5994-6002 doi: 10.3748/wjg.v23.i32.5994
36
Kandy T Velázquez, Reilly T Enos, Jackie E Bader, Alexander T Sougiannis, Meredith S Carson, Ioulia Chatzistamou, James A Carson, Prakash S Nagarkatti, Mitzi Nagarkatti, E Angela Murphy. Prolonged high-fat-diet feeding promotes non-alcoholic fatty liver disease and alters gut microbiota in miceWorld Journal of Hepatology 2019; 11(8): 619-637 doi: 10.4254/wjh.v11.i8.619
37
Eleonora Cremonini, Ziwei Wang, Ahmed Bettaieb, Ana M. Adamo, Elena Daveri, David A. Mills, Karen M. Kalanetra, Fawaz G. Haj, Sidika Karakas, Patricia I. Oteiza. (-)-Epicatechin protects the intestinal barrier from high fat diet-induced permeabilization: Implications for steatosis and insulin resistanceRedox Biology 2018; 14: 588 doi: 10.1016/j.redox.2017.11.002
38
Haluk Tarik KANI, İlknur DELIKTAS, Yusuf YILMAZ. Prevalence of fatty liver disease in patients with inflammatory bowel disease: a transient elastography study on the basis of a controlled attenuation parameterMarmara Medical Journal 2019; 32(2): 68 doi: 10.5472/marumj.570907
39
Min Chen, Yanke Lin, Yongkang Dang, Yifei Xiao, Fugui Zhang, Guanghui Sun, Xuejun Jiang, Li Zhang, Jianhao Du, Shuyi Duan, Xiaojian Zhang, Zifei Qin, Jing Yang, Kaisheng Liu, Baojian Wu. Reprogramming of rhythmic liver metabolism by intestinal clockJournal of Hepatology 2023; 79(3): 741 doi: 10.1016/j.jhep.2023.04.040
40
Varun Chandrashekaran, Ratanesh K. Seth, Diptadip Dattaroy, Firas Alhasson, Jacek Ziolenka, James Carson, Franklin G. Berger, Balaraman Kalyanaraman, Anna Mae Diehl, Saurabh Chatterjee. HMGB1-RAGE pathway drives peroxynitrite signaling-induced IBD-like inflammation in murine nonalcoholic fatty liver diseaseRedox Biology 2017; 13: 8 doi: 10.1016/j.redox.2017.05.005
41
Kwang Il Seo, Sang-Bum Kang. Hepatobiliary Manifestation of Inflammatory Bowel DiseaseThe Korean Journal of Gastroenterology 2019; 73(5): 248 doi: 10.4166/kjg.2019.73.5.248
42
Wojciech Marlicz, Karolina Skonieczna-Żydecka, Konstantinos John Dabos, Igor Łoniewski, Anastasios Koulaouzidis. Emerging concepts in non-invasive monitoring of Crohn’s diseaseTherapeutic Advances in Gastroenterology 2018; 11: 175628481876907 doi: 10.1177/1756284818769076
43
Scott McHenry, Ankita Tirath, Richard Tsai, Yeshika Sharma, Avegail G Flores, Nicholas O Davidson, Kathryn J Fowler, Matthew A Ciorba, Parakkal Deepak. Derivation and Internal Validation of a Clinical Prediction Tool to Predict Nonalcoholic Fatty Liver Disease in Patients With Crohn’s DiseaseInflammatory Bowel Diseases 2020; 26(12): 1917 doi: 10.1093/ibd/izz324
44
Andrew Szilagyi. Relationship(s) between obesity and inflammatory bowel diseases: possible intertwined pathogenic mechanismsClinical Journal of Gastroenterology 2020; 13(2): 139 doi: 10.1007/s12328-019-01037-y
45
Rui Gaspar, Catarina Castelo Branco, Guilherme Macedo. Liver manifestations and complications in inflammatory bowel disease: A reviewWorld Journal of Hepatology 2021; 13(12): 1956-1967 doi: 10.4254/wjh.v13.i12.1956
46
Macarena Klein, Paulina Núñez, Constanza Bay, Carolina Pizarro, Rocío Sedano, Rodrigo Quera. Liver Disorders in Inflammatory Bowel DiseaseEMJ Hepatology 2020; : 26 doi: 10.33590/emjhepatol/20-00040
47
Yahav Eilam, Hamdan Khattib, Noam Pintel, Dorit Avni. Microalgae—Sustainable Source for Alternative Proteins and Functional Ingredients Promoting Gut and Liver HealthGlobal Challenges 2023; 7(5) doi: 10.1002/gch2.202200177
48
Zhiyuan Wei, Jiangbin Wang. Exploration of the core pathway of inflammatory bowel disease complicated with metabolic fatty liver and two-sample Mendelian randomization study of the causal relationships behind the diseaseFrontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1375654
49
Charalampia Amerikanou, Efstathia Papada, Aristea Gioxari, Ilias Smyrnioudis, Stamatia-Angeliki Kleftaki, Evdokia Valsamidou, Victoria Bruns, Rajarshi Banerjee, Maria Giovanna Trivella, Natasa Milic, Milica Medić-Stojanoska, Amalia Gastaldelli, Aimo Kannt, George V. Dedoussis, Andriana C. Kaliora. Mastiha has efficacy in immune-mediated inflammatory diseases through a microRNA-155 Th17 dependent actionPharmacological Research 2021; 171: 105753 doi: 10.1016/j.phrs.2021.105753
50
Chang-Kee Hyun. Molecular and Pathophysiological Links between Metabolic Disorders and Inflammatory Bowel DiseasesInternational Journal of Molecular Sciences 2021; 22(17): 9139 doi: 10.3390/ijms22179139
51
Zixuan Zhong, Minxuan Xu, Chenxu Ge, Jun Tan. Exploring shared molecular signatures and regulatory mechanisms in nonalcoholic steatohepatitis and inflammatory bowel disease using integrative bioinformatics analysisScientific Reports 2024; 14(1) doi: 10.1038/s41598-024-62310-w
52
Zi-Yuan Zou, Bo Shen, Jian-Gao Fan. Systematic Review With Meta-analysis: Epidemiology of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel DiseaseInflammatory Bowel Diseases 2019; 25(11): 1764 doi: 10.1093/ibd/izz043
53
Jeonghyeon Kwon, Chungho Lee, Sungbaek Heo, Bobae Kim, Chang-Kee Hyun. DSS-induced colitis is associated with adipose tissue dysfunction and disrupted hepatic lipid metabolism leading to hepatosteatosis and dyslipidemia in miceScientific Reports 2021; 11(1) doi: 10.1038/s41598-021-84761-1
54
Austin Lin, Hannah Roth, Adjoa Anyane-Yeboa, David T Rubin, Sonali Paul. Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysisInflammatory Bowel Diseases 2021; 27(6): 947 doi: 10.1093/ibd/izaa189
55
Min Kyu Kang, Kyeong Ok Kim, Min Cheol Kim, Jung Gil Park, Byung Ik Jang. Sarcopenia Is a New Risk Factor of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel DiseaseDigestive Diseases 2020; 38(6): 507 doi: 10.1159/000506938
56
S. V. Okovity, K. L. Raikhelson, A. V. Volnukhin, D. A. Kudlai. Hepatoprotective properties of glycyrrhizic acidExperimental and Clinical Gastroenterology 2020; (12): 96 doi: 10.31146/1682-8658-ecg-184-12-96-108
57
Rossella Maresca, Irene Mignini, Simone Varca, Valentin Calvez, Fabrizio Termite, Giorgio Esposto, Lucrezia Laterza, Franco Scaldaferri, Maria Elena Ainora, Antonio Gasbarrini, Maria Assunta Zocco. Inflammatory Bowel Diseases and Non-Alcoholic Fatty Liver Disease: Piecing a Complex Puzzle TogetherInternational Journal of Molecular Sciences 2024; 25(6): 3278 doi: 10.3390/ijms25063278
58
Antoine Boustany, Romy Rahhal, Jad Mitri, Somtochukwu Onwuzo, Hadi Khaled Abou Zeid, György Baffy, Myriam Martel, Alan N. Barkun, Imad Asaad. The impact of nonalcoholic fatty liver disease on inflammatory bowel disease-related hospitalization outcomes: a systematic reviewEuropean Journal of Gastroenterology & Hepatology 2023; 35(10): 1067 doi: 10.1097/MEG.0000000000002607
59
Rosellina Margherita Mancina, Daniele De Bonis, Raffele Pagnotta, Cristina Cosco, Vincenzo Cosco, Tiziana Montalcini, Arturo Pujia, Patrizia Doldo, Rocco Spagnuolo. Ulcerative Colitis as an Independent Risk Factor for Hepatic SteatosisGastroenterology Nursing 2020; 43(4): 292 doi: 10.1097/SGA.0000000000000461
60
Shaghayegh Baradaran Ghavami, Hamid Asadzadeh Aghdaei, Dario Sorrentino, Shabnam Shahrokh, Maryam Farmani, Fatemeh Ashrafian, Maria Pina Dore, Shahrbanoo Keshavarz Azizi Raftar, Seyed Mobin Khoramjoo, Mohammad Reza Zali. Probiotic-Induced Tolerogenic Dendritic Cells: A Novel Therapy for Inflammatory Bowel Disease?International Journal of Molecular Sciences 2021; 22(15): 8274 doi: 10.3390/ijms22158274